(Q43040442)

12 November 2017

title

Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease (English)

1 reference

12 November 2017

David Sperandio

1

1 reference

12 November 2017

Anthony R Gangloff

2

1 reference

12 November 2017

Joane Litvak

3

1 reference

12 November 2017

Richard Goldsmith

4

1 reference

12 November 2017

Jason M Hataye

5

1 reference

12 November 2017

Vivian R Wang

6

1 reference

12 November 2017

Emma J Shelton

7

1 reference

12 November 2017

Kyle Elrod

8

1 reference

12 November 2017

James W Janc

9

1 reference

12 November 2017

James M Clark

10

1 reference

12 November 2017

Ken Rice

11

1 reference

12 November 2017

Steve Weinheimer

12

1 reference

12 November 2017

Kap-Sun Yeung

13

1 reference

12 November 2017

Nicholas A Meanwell

14

1 reference

12 November 2017

Dennis Hernandez

15

1 reference

12 November 2017

Andrew J Staab

16

1 reference

12 November 2017

Brian L Venables

17

1 reference

12 November 2017

Jeffrey R Spencer

18

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Bioorganic & Medicinal Chemistry Letters

12 November 2017

published in

1 reference

12 November 2017

volume

12

1 reference

12 November 2017

issue

21

1 reference

12 November 2017

page(s)

3129-3133

1 reference

The scientific challenge of hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Hepatitis C: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Risk factors for the rising rates of primary liver cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Emerging therapies for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Replication of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Non-peptide inhibitors of HCV serine proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Design of potent selective zinc-mediated serine protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2802%2900680-7

7 January 2021

10.1016/S0960-894X(02)00680-7

Identifiers

DOI

1 reference

12 November 2017

1 reference